Q1 2015 13F Holders as of 31 Mar 2015
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Total 13F shares
-
20,572,529
-
Share change
-
+778,569
-
Total reported value
-
$426,440,171
-
Put/Call ratio
-
164%
-
Price per share
-
$20.73
-
Number of holders
-
69
-
Value change
-
+$18,581,352
-
Number of buys
-
42
-
Number of sells
-
24
Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2015
As of 31 Mar 2015,
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by
69 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,572,529 shares.
The largest 10 holders included
Essex Woodlands Health Ventures, Inc., FRANKLIN RESOURCES INC, NQ HCIF GP, Ltd., JPMORGAN CHASE & CO, Bank of New York Mellon Corp, Visium Asset Management, LP, Polar Capital LLP, Arrowpoint Asset Management, LLC, BlackRock Fund Advisors, and VANGUARD GROUP INC.
This page lists
69
institutional shareholders reporting positions in this security
for the Q1 2015 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.